[Targeted degradation of androgen receptors in androgen-independent prostate cancer cells: an experimental study]. 2009

Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
Department of Urology, The First People's Hospital Afiliated to Shanghai Jiaotong University, Shanghai 200080, China.

OBJECTIVE To investigate targeted degradation of the androgen receptor (AR) by chimeric molecules (DHT-PROTAC) via the ubiquitin-proteasome pathway in androgen-independent prostate cancer CA-2B cells, and explore the proliferation, secretion and apoptosis of the treated cells. METHODS C4-2B cells were treated with DHT-PROTAC, and then the expressions of the AR protein and caspase3 in the C4-2B cells were detected by immunohistochemistry and Western blot. The concentration of PSA in the supernatant was examined by ELISA. The cells were counted and their proliferation analyzed by a growth curve. The inhibitory effect on the growth of C4-2B cells was evaluated by MIT assay. RESULTS Compared with the control group, the DHT-PROTAC-treated group showed an obviously decreased expression of AR proteins with a significant attenuation of the band signals (P < 0.05), a 40% reduction of the AR-positive cells and a 60% decrease of the PSA concentration in the supernatant (P < 0.05). DHT-PROTAC exhibited an inhibitory effect on the C4-2B cells in a time-dependant manner (P < 0.05). CONCLUSIONS The chimeric molecule (DHT-PROTAC) can target the degradation of androgen receptors, reduce the secretion of PSA and repress the in vitro growth of C4-2B cells.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
February 2004, The Journal of urology,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
August 1997, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
October 2014, La Revue de medecine interne,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
May 2002, Cancer gene therapy,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
May 2023, Oncology reports,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
October 1995, The New England journal of medicine,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
January 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
December 2004, BJU international,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
September 2000, The Prostate,
Yun-Feng Shi, and Yue-Qing Tang, and Xiao-Wen Sun, and Dian-Jun Yu, and Bang-Min Han, and Yan Hong, and Shu-Jie Xia
October 2022, ACS medicinal chemistry letters,
Copied contents to your clipboard!